- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
American Oncology Network Included in 2022 Inc. 5000 Annual List
The American Oncology Network was ranked number 107 on the 2022 Inc. 5000 Annual List.
Fort Myers, Fla., August 18, 2022 – American Oncology Network, LLC (AON) was ranked number 107 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. AON also received the number 8 position in the health services category.
Among the top 500, the average median 3-year revenue growth rate soared to 2144%. Together, those companies added more than 68,394 jobs over the past 3 years.
“We are honored to be recognized as one of the nation’s fastest-growing private companies by Inc.,” said AON chief executive officer Todd Schonherz. “At AON, we believe the key to accessible and equitable health care lies in the strength of community healthcare practices, which is why we strive to support community oncology practices, large and small. This recognition is a reminder that we are taking the right steps in forwarding our mission by providing support and resources for hometown oncology practices and breaking down barriers to cancer care.”
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More
